Document is current
Any future updates will be listed below
-
Authors
Yuan, Shuai https://orcid.org/0000-0001-5055-5627
Chen, Jie https://orcid.org/0000-0002-4029-4192
Ruan, Xixin https://orcid.org/0000-0002-4937-9168
Li, Yuying https://orcid.org/0000-0002-3231-7542
Abramowitz, Sarah A.
Wang, Lijuan https://orcid.org/0000-0002-9797-0753
Jiang, Fangyuan
Xiong, Ying https://orcid.org/0000-0001-7644-014X
Levin, Michael G. https://orcid.org/0000-0002-9937-9932
Voight, Benjamin F. https://orcid.org/0000-0002-6205-9994
Gill, Dipender https://orcid.org/0000-0001-7312-7078
Burgess, Stephen https://orcid.org/0000-0001-5365-8760
Åkesson, Agneta https://orcid.org/0000-0001-9594-4140
Michaëlsson, Karl
Li, Xue https://orcid.org/0000-0001-6880-2577
Damrauer, Scott M. https://orcid.org/0000-0001-8009-1632
Larsson, Susanna C. https://orcid.org/0000-0003-0118-0341
-
Funding
Funding for this research was provided by:
American Heart Association (24POST1189614)
Vetenskapsrådet
Forskningsrådet om Hälsa, Arbetsliv och Välfärd
Hjärt-Lungfonden
Swedish Cancer Foundation
- License Information
-
More Information
Article History
Received: 30 September 2024
Accepted: 1 July 2025
First Online: 11 July 2025
Competing interests
: S.M.D. receives research support from RenalytixAI and in-kind research support from Novo Nordisk, both outside the scope of the current project. D.G. is the Chief Executive Officer of Sequoia Genetics, a private limited company that works with investors, pharma, biotech, and academia by performing research that leverages genetic data to help inform drug discovery and development. D.G. has financial interests in several biotechnology companies. Other authors declare no competing interests.
